【摘要】 鼠类肉瘤病毒癌基因同源物B1(BRAF)基因是非小细胞肺癌(NSCLC)的驱动基因之一,在NSCLC中突变率为0.5%~4.9%,其中V600E突变类型占到一半以上。BRAF突变多见于女性、肺腺癌患者,亚裔人群中突变率相对较低。BRAF突变可与其他基因突变,如EGFR、K-Ras突变共存,但其临床意义尚不清楚。全球NSCLC患者数量庞大,尽管BRAF突变率在NSCLC中较低,低突变率基因及其靶向治疗的研究仍然相当重要。目前BRAF抑制剂治疗NSCLC正在临床试验中。本文就NSCLC中BRAF突变及靶向治疗的研究进展进行综述。更多还原

【Abstract】 BRAF mutation is one of driver mutations in non-small cell lung cancer( NSCLC). BRAF mutation rate is about0. 5% ~ 4. 9%,and more than half of BRAF mutation is V600 E. BRAF mutation occurs more commonly in female patients with adenocarcinoma,and the mutation rate is much lower in Asian people. The clinical significance of coexistence of BRAF mutation and other mutations,such as EGFR and K-Ras mutations was yet unknown. Given the huge global burden of lung cancer,progress of BRAF mutation studies hold significant importance,despite its low mutation rate overall. Currently,several BRAF inhibitors are being studied in clinical trials for patients with NSCLC. This review is intended to outline the recent advances of BRAF mutation and its targeted therapy in NSCLC.更多还原